About Us
Sinotau follows a strategy of “sourcing and introducing cutting-edge technology + in-house R&D” to reduce the gap between U.S.A. and Europe with China in the development of radiopharmaceuticals. Since 2014, Sinotau has cooperated with leading pharma players and research institutions across Europe and U.S.A., and has obtained the rights to develop and commercialize a number of key radiopharmaceutical products in China and globally.
Cerveau Technologies is a joint venture between Sinotau Pharmaceutical Group and Enigma Biomedical Group, a Canadian company. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease and Parkinson's disease.
Cerveau has developed collaboration platforms with multiple pharmaceutical international companies to support therapy development utilizing molecular imaging biomarkers.
Sinotau signs an agreement with Navidea Biopharmaceuticals Inc., for the exclusive China distribution rights of Technetium (99mTc) tilmanocept, the first and only receptor-targeted lymphatic mapping agent approved by the FDA.
Sinotau signs exclusive agreement with FluoroPharma Medical Imaging, Inc., an US company, to develop and commercialize cardiac imaging products CardioPET and BFPET in China and Canada.
Cerveau signs exclusive license agreement with Merck Sharp & Dohme for the global development and commercialization of early stage investigational imaging agent MK-6240.
Sinotau signs license agreement with Piramal Imaging S.A., for development and commercialization of Neuraceq, a novel Aβ amyloid imaging diagnostic agent for Alzheimer's disease, in China.
Receives from NIH A Grant of Exclusive Patent License of Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
